Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related b...
Apnimed director Paul J. Sekhri acquires $200,000 in common shares
Apnimed adopts new IPO-era bylaws with advance notice rules for shareholder proposals
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | APMD Stock News
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Pre-market hot trades in US stocks: Zeta Network up 9.24% in pre-market; Apnimed down 8.60% in pre-market
US IPO Weekly Winners & Losers